IFP Advisors’s Standard BioTools LAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$105 Sell
142
-1,227
-90% -$943 ﹤0.01% 4974
2026
Q2
$1.13K Buy
1,369
+1,051
+331% +$993 ﹤0.01% 4461
2026
Q1
$292 Sell
318
-471
-60% -$570 ﹤0.01% 4542
2025
Q4
$1.01K Hold
789
– – ﹤0.01% 4069
2025
Q3
$1.03K Sell
789
-30
-4% -$39 ﹤0.01% 3955
2025
Q2
$982 Buy
+819
New +$908 ﹤0.01% 4233
2025
Q1
– Sell
-7
Closed -$12 – 4502
2024
Q4
$12 Buy
+7
New +$13 ﹤0.01% 4517
2023
Q1
– Sell
-1,527
Closed -$9K – 3977
2022
Q4
$9K Sell
1,527
-401
-21% -$494 ﹤0.01% 3457
2022
Q3
$11K Sell
1,928
-609
-24% -$921 ﹤0.01% 3584
2022
Q2
$14K Hold
2,537
– – ﹤0.01% 3148
2022
Q1
$14K Buy
+2,537
New +$8.76K ﹤0.01% 3148

Other funds holding LAB

IFP Advisors's LAB Position: Q3 2026 in Review

IFP Advisors reduced its Standard BioTools (LAB) stake by 90% in Q3 2026, selling an estimated $943 and leaving 142 shares worth $105. The position accounts for ﹤0.01% of the portfolio, ranked #4974.

IFP Advisors first reported a position in LAB in Q1 2022 and has held it in 11 quarters since. The position peaked at $14K in Q2 2022. 3 funds tracked by Wall St. Rank hold LAB as of Q3 2026.

  • IFP Advisors held 142 shares of Standard BioTools worth $105 as of Q3 2026.
  • IFP Advisors sold 1,227 Standard BioTools shares in Q3 2026, an estimated $943.
  • Standard BioTools made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #4974 holding.
  • IFP Advisors first reported a position in Standard BioTools in Q1 2022 and has held it in 11 quarters since.
  • IFP Advisors's Standard BioTools position peaked at $14K in Q2 2022.
  • 3 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.